Kiniksa Pharmaceuticals International, plc (KNSA)

Market Cap	1.68B
Revenue (ttm)	423.24M
Net Income (ttm)	-43.19M
Shares Out	72.64M
EPS (ttm)	-0.60
PE Ratio	n/a
Forward PE	22.45
Dividend	n/a
Ex-Dividend Date	n/a

Volume	555,011
Open	23.21
Previous Close	23.36
Day's Range	22.82 - 23.36
52-Week Range	16.56 - 28.15
Beta	0.48
Analysts	Strong Buy
Price Target	37.17 (+60.98%)
Earnings Date	Apr 22, 2025

About KNSA

Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company, developing and commercializing novel therapies for diseases with unmet need and focuses on cardiovascular indications worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-387, an in...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• IPO Date: May 24, 2018
• Employees: 315
• Stock Exchange: NASDAQ
• Ticker Symbol: KNSA
• Website: https://www.kiniksa.com

Analyst Forecast

According to 6 analysts, the average rating for KNSA stock is "Strong Buy." The 12-month stock price forecast is $37.17, which is an increase of 60.98% from the latest price.

Price Target

$37.17

(60.98% upside)

Analyst Consensus: Strong Buy